BNTX Q3 2025 Earnings
Reported Nov 3, 2025 at 6:49 AM ET · SEC Source
Q3 25 EPS
$-0.12
MISS 220.36%
Est. $0.10
Q3 25 Revenue
N/A
Est. $1.01B
vs S&P Since Q3 25
-10.7%
TRAILING MARKET
BNTX -5.2% vs S&P +5.5%
Market Reaction
Did BNTX Beat Earnings? Q3 2025 Results
BioNTech delivered a sharply mixed third quarter, posting an earnings-per-share loss of $0.12 against a consensus estimate of $0.10, a miss of 220.36%, even as revenues of $1.52 billion topped the $1.01 billion consensus and rose 22% year-over-year. … Read more BioNTech delivered a sharply mixed third quarter, posting an earnings-per-share loss of $0.12 against a consensus estimate of $0.10, a miss of 220.36%, even as revenues of $1.52 billion topped the $1.01 billion consensus and rose 22% year-over-year. The headline loss, which swung from a $198.10 million net profit in Q3 2024 to a net loss of $28.70 million, was driven primarily by $678.50 million in settlement expenses tied to patent litigation with CureVac and GSK. Beneath that charge, the quarter carried genuine strategic momentum: a landmark out-licensing deal with Bristol-Myers Squibb for cancer candidate pumitamig contributed $613.00 million in recognized revenue from a $1.50 billion upfront payment, propelling operating cash flow to $780.70 million, a sharp reversal from a $638.90 million outflow a year earlier. The company is now advancing toward a BLA filing for trastuzumab pamirtecan in endometrial cancer in 2026, signaling its transition toward becoming a multi-product oncology company, though it cautioned that significant and increasing operating expenses lie ahead.
Key Takeaways
- • BMS pumitamig partnership generated €613.0 million in out-licensing revenue in Q3 2025
- • COVID-19 vaccine revenues declined 23% YoY due to lower dose volumes sold
- • CureVac/GSK patent settlement drove €678.5 million in other operating expenses
- • Non-COVID R&D spending increased 21% to €528.0 million in Q3 from late-stage oncology trial starts
- • General and administrative expenses decreased 8% from reduced external services
- • Finance income declined 52% due to lower interest income and negative FX effects
- • Q3 operating cash flow of €780.7 million driven by BMS upfront payment receipt, reversing €638.9 million outflow in Q3 2024
- • Capital expenditures declined to €41.9 million from €79.1 million YoY reflecting reduced facility investment
BNTX YoY Financials
Q3 2025 vs Q3 2024, source: SEC Filings
BNTX Revenue by Segment
Business unit performance breakdown
BNTX Earnings Trends
BNTX vs Market 30 Day Price Reactions
30-day stock return vs benchmark after each earnings
BNTX EPS Trend
Earnings per share: estimate vs actual
BNTX Revenue Trend
Quarterly revenue: estimate vs actual
BNTX Quarterly Results
4 quarters of earnings data
| Quarter | EPS Est. | EPS Act. | Surprise | Revenue | Rev. Surprise |
|---|---|---|---|---|---|
| Q1 26 | $-2.14 | — | — | — | — |
| Q4 25 MISS FY | $-0.25 | $-1.25 | -405.66% | $907.4M | +24.34% |
| FY Full Year | $-3.44 | $-4.70 | -36.62% | $2.87B | +6.60% |
| Q3 25 MISS | $0.10 | $-0.12 | -220.36% | — | — |
| Q2 25 MISS | $-1.41 | $-1.85 | -31.65% | $301.6M | +14.39% |